Athonis Therapeutics is an Australian biopharmaceutical and digital health company developing small molecule treatments for genetically defined and idiopathic neurodevelopmental diseases as well as a neuropsychiatric condition. There are no approved treatments for the core symptoms of these conditions.
Athonis has a patent pending on a novel combination of small-molecule compounds covering four indications, led by two rare paediatric genetic disorders. Athonis is preparing its first preclinical efficacy study in a validated Fragile X Syndrome model.
Athonis is advancing a novel small molecule combination across four neurodevelopmental and neuropsychiatric indications, united by a common validated biological pathway.
| Indication | Status |
|---|---|
| Fragile X Syndrome | Study plan in development, specialist CRO identified |
| Phelan-McDermid Syndrome | Specialist CRO scoping underway |
| Autism Spectrum Disorder | Preclinical pathway being evaluated |
| Neuropsychiatric Indication | Mechanistic rationale |
Fragile X Syndrome is the most common inherited cause of intellectual disability and the most common single-gene cause of autism. There is no approved pharmacological treatment for its core symptoms. Athonis is preparing a preclinical efficacy study of its novel small-molecule combination in a validated genetic model, and plans to work with a specialist contract research organisation with an established track record in Fragile X models.
Phelan-McDermid Syndrome is a genetically defined neurodevelopmental disorder caused by deletion or mutation of the SHANK3 gene, with no approved pharmacological treatment for its core symptoms. Athonis is scoping a preclinical efficacy programme for Phelan-McDermid Syndrome with the same specialist contract research organisation it plans to work with on its Fragile X Syndrome programme, building on that organisation's prior experience in this genetic model.
Autism spectrum disorder affects an estimated 62 million people globally, with no approved pharmacological treatment for its core symptoms despite decades of research. Athonis's preclinical pathway for idiopathic autism spectrum disorder is under active review, building on the same biological pathway implicated in its genetically defined programmes.
Athonis's fourth indication addresses a major unmet need in neuropsychiatry where the negative symptom burden remains almost entirely untreated by existing pharmacotherapy. The same biological pathway targeted by the Athonis combination has established mechanistic relevance to this indication through published human genetics and preclinical data. Athonis intends to pursue this indication as a pipeline extension.
Earlier clarity for parents. Better outcomes for children.
Athonis's patent-pending digital platform differs from static quizzes. The eScreener sits at the intersection of early childhood development, autism, and support-needs identification — informed by clinicians, researchers, and parents.
Unlike traditional autism screeners, the eScreener classifies the likely intensity of developmental support a child may need, generating a structured output that maps to the language used by clinicians, early intervention services, and support frameworks including the NDIS.
Find out what support your child may need — and what to do next. Peace of mind comes from knowledge.
We believe that earlier identification of a child's developmental support needs leads to better outcomes for children and families. Our tools are designed to support those conversations, not replace clinical judgement.
Developed with clinical input, developmental research, and real parent feedback.
Designed for parents and primary health practitioners — no clinical administration required.
Outputs structured next-step guidance, not just a score — supporting navigation of health and support systems.
A patent-pending, computer-implemented developmental support-classification tool designed for parents of toddlers aged 18–36 months who have questions about their child's development or support needs. The eScreener is not intended to replace clinical assessment but to support it.
Athonis is developing an Enterprise Edition of the eScreener as part of a broader Consumer, Enterprise and Clinical Trial platform strategy. The Enterprise Edition is designed for federal and state government agencies, local health districts, maternal and child health services, early childhood intervention providers, paediatricians and healthcare providers, including mapping to NDIS pathways and programmes such as Thriving Kids.
Early institutional and clinical engagement is underway for an Enterprise developmental product.
Building on the parent-facing platform, the Enterprise Edition is intended to provide a centralised administrative dashboard, population-level reporting and analytics, and interoperability with existing state and federal health infrastructure, including My Health Record.
The same underlying platform is also being developed as a clinical trial stratification tool, supporting patient identification and enrichment for Athonis's own therapeutic clinical trials as they progress.
The Enterprise Edition is being designed with public sector requirements in mind, including data sovereignty, Privacy Act 1988 compliance and alignment with Australian government security frameworks. Athonis welcomes conversations with agencies interested in shaping the Enterprise roadmap or participating in a structured pilot programme.
Athonis Therapeutics is an Australian biopharmaceutical and digital health company focused on finding new therapies and pathways for unmet neurodevelopmental and neuropsychiatric conditions.
We bring together expertise in drug development, clinical research, and digital health to address neurodevelopmental and neuropsychiatric conditions where effective treatments remain limited or absent.
Whether you are a clinician, health service, government department or agency, researcher, media or parent — we welcome enquiries about the eScreener, pilot programs, partnerships, or our therapeutics.